References
Strupp M, Zwergal A, Brandt T (2007) Episodic ataxia type 2. Neurotherapeutics 4(2):267–273
Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K (2011) A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77(3):269–275. https://doi.org/10.1212/WNL.0b013e318225ab07
Van Bogaert P, Szliwowski H (1996) EEG findings in acetazolamide-responsive hereditary paroxysmal ataxia. Neurophysiol Clin 26(5):335–340
Rajakulendran S, Graves TD, Labrum RW, Kotzadimitriou D, Eunson L, Davis MB, Davies R, Wood NW, Kullmann DM, Hanna MG, Schorge S (2010) Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy. J Physiol 588(Pt 11):1905–1913. https://doi.org/10.1113/jphysiol.2009.186437
Mantuano E, Romano S, Veneziano L, Gellera C, Castellotti B, Caimi S, Testa D, Estienne M, Zorzi G, Bugiani M, Rajabally YA, Barcina MJ, Servidei S, Panico A, Frontali M, Mariotti C (2010) Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. J Neurol Sci 291(1–2):30–36. https://doi.org/10.1016/j.jns.2010.01.010
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30
Park J, Oh HM, Park HJ, Cho AR, Lee DW, Jang JH, Jang DH (2019) Usefulness of comprehensive targeted multigene panel sequencing for neuromuscular disorders in Korean patients. Mol Genet Genomic Med 7(10):e00947. https://doi.org/10.1002/mgg3.947
Kotagal V Acetazolamide-responsive ataxia. In: Seminars in neurology, 2012. vol 05. Thieme Medical Publishers, pp 533–537
Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62(9):1623–1625
Surges R, Volynski KE, Walker MC (2008) Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord 1(1):13–24
Lee H, Jang DH, Jang JH, Kim T (2017) Effectiveness of levetiracetam in an acetazolamide-unresponsive patient with episodic ataxia type 2 by a novel CACNA1A nonsense mutation. Eur J Neurol 24(7):e43–e44. https://doi.org/10.1111/ene.13327
Kaido M, Furuta M, Nakamori M, Yuasa Y, Takahashi MP (2016) Episodic ataxia type 2 manifests as epileptiform electroencephalographic activity with no epileptic attacks in two family members. Rinsho Shinkeigaku 56(4):260–264. https://doi.org/10.5692/clinicalneurol.cn-000854
Cordeau JP (1959) Monorhythmic frontal delta activity in the human electroencephalogram: a study of 100 cases. Electroencephalogr Clin Neurophysiol 11:733–746. https://doi.org/10.1016/0013-4694(59)90113-0
Sutter R, Stevens RD, Kaplan PW (2013) Clinical and imaging correlates of EEG patterns in hospitalized patients with encephalopathy. J Neurol 260(4):1087–1098. https://doi.org/10.1007/s00415-012-6766-1
Author information
Authors and Affiliations
Contributions
SN wrote the manuscript. TK supervised the project.
Corresponding author
Ethics declarations
Ethical approval
The authors declare that these case reports has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent was obtained from the patients and The Institutional Review Board at Incheon St. Mary’s Hospital approved this case report.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Na, S., Kim, T. Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports . Neurol Sci 42, 3897–3899 (2021). https://doi.org/10.1007/s10072-021-05368-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-021-05368-y